PROG experienced an increase of 7.21% in the premarket. The last trading session closed at $0.06 with an increase of 5.71%.
Participation in the Upcoming Investor Conferences by PROG
PROG has announced on 3rd September 2021 that it would take part in two forthcoming virtual investor conferences:
- On September 13, 2021, at 7 a.m. ET / 4 a.m. PT, a pre-recorded presentation from H.C. Wainwright’s 23rd Annual Global Investment Conference will be posted on Progenity’s website and will be accessible for 90 days: and
- On September 15, 2021, at 7:55 a.m. ET / 4:55 a.m. PT, at Baird’s 2021 Global Healthcare Conference will take place.
PROG announces Second Quarter 2021 Financial Results
On August 12, 2021, PROG announced its second-quarter 2021 financial results. For the three months ended June 30, 2021, operating expenditures were $36.1 million.
The net loss for the three months ended June 30, 2021, was $78.5 million, or $1.23 per share. For the three months ended June 30, 2021, the net loss from discontinued operations was $37.1 million, with a net loss per share of $0.58.
Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
On 29 June 2021 PROG reported that the validation study for its PreecludiaTM rule-out test for preeclampsia was completed successfully, with the primary goal of the research protocol met.
The PRO-104 clinical validation research included approximately 1,300 people in a prospective, multi-center observational study. Pregnant women from 18 to 45 years old with a gestational age of 28 0/7 to 36 6/7 weeks provided test specimens. The research was conducted under the guise of anonymity.
At 20 labor and delivery triage sites across the United States, patients in the research group came with possible signs and symptoms of preeclampsia. The patient demographics were similar to those of the at-risk group in the United States.
Appointment Modification
Surbhi Sarna was appointed to the board of directors of Progenity, Inc (PROG) on June 30, 2021, with effect from July 1, 2021. Ms. Surbhi’s medical device experience, as well as her focus on strategic relationship development, will be beneficial as the business moves forward with its innovation pipeline.
